keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28719450/combination-of-177lu-psma-617-and-external-radiotherapy-for-the-treatment-of-cerebral-metastases-in-patients-with-castration-resistant-metastatic-prostate-cancer
#1
Xiao Wei, Carl Schlenkhoff, Bettina Schwarz, Markus Essler, Hojjat Ahmadzadehfar
Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to the brain metastases. Prior to the combined therapy, all systemic metastases, including cerebral lesions, showed PSMA expression using Ga-PSMA PET/CT. Under the combined therapy, all the metastases, particularly the cerebral lesions, showed significant regression in size and PSMA expression over time...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28719448/biopsy-proven-diffuse-mediastinal-prostate-cancer-metastases-negative-on-18f-fluorocholine-diagnosed-on-68ga-psma-and-18f-psma-pet-ct
#2
Guillaume Chaussé, Tamim Niazi, Gad Solomon Abikhzer, Stephan Michael Probst
A 72-year-old man with prostate cancer (stage T3b, Gleason score 7) treated by radical prostatectomy was found to have biochemical failure (prostate-specific antigen 8.5 ng/mL) and a suspicious growing nodularity at the left prostate bed on MRI. F-fluorocholine PET/CT failed to demonstrate any site of uptake suggestive of malignancy. A bone scan did exclude bone metastases. Ga-PSMA PET/CT revealed various positive lymph nodes in the supraclavicular, mediastinal, and hilar regions. This was confirmed on F-DCFPyl PET/CT, with the addition of a suspicious right axillary lymph node...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28719112/defining-the-clinical-utility-of-psma-targeted-pet-imaging-of-prostate-cancer
#3
EDITORIAL
Michael A Gorin, Martin G Pomper, Kenneth J Pienta, Steven P Rowe
No abstract text is available yet for this article.
August 2017: BJU International
https://www.readbyqxmd.com/read/28716214/early-68-ga-psma-pet-mri-acquisition-assessment-of-lesion-detectability-and-pet-metrics-in-patients-with-prostate-cancer-undergoing-same-day-late-pet-ct
#4
L Domachevsky, H Bernstine, N Goldberg, M Nidam, D Stern, J Sosna, D Groshar
AIM: To compare lesion detectability and positron-emission tomography (PET) metric measurements between early-PET/magnetic resonance imaging (MRI) acquisition and same-day PET/computed tomography (CT). MATERIALS AND METHODS: The study was approved by the institutional review board and written informed consent was obtained from all patients. Twenty-one patients underwent non-time-of-flight (TOF) PET/MRI immediately following (68)GA-prostate-specific membrane antigen (PSMA) tracer injection in two steps: firstly, early prostate PET/MRI (pPET/MRI) and early whole-body (WB) PET/MRI (wbPET/MR) followed by WB TOF PET/CT (wbPET/CT)...
July 14, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28715042/-diagnostic-significance-of-multiparametric-mri-combined-with-us-fusion-guided-biopsy-of-the-prostate-in-patients-with-increased-psa-levels-and-negative-standard-biopsy-results-to-detect-significant-prostate-cancer-correlation-with-the-gleason-score-korrelation
#5
Manuela Hoffmann, Manuela A Hoffmann, Helmut J Wieler, Frank M Jakobs, Kasra Taymoorian, Arnd Gerhards, Matthias Miederer, Mathias Schreckenberger
AIMS: To increase diagnostic precision and to reduce overtreatment of low-risk malignant disease, multiparametric MRI (mpMRI) combined with ultrasound (US) fusion guided biopsy of the prostate were performed. METHODS: In 99 male patients with increased PSA plasma levels and previous negative standard biopsy procedures, mpMRI was carried out followed by US fusion guided perineal biopsy. PI-RADS-Data (PS) of mpMRI and histopathological Gleason score (GS) were categorized and statistically compared...
July 17, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28711780/localised-delivery-of-doxorubicin-to-prostate-cancer-cells-through-a-psma-targeted-hyperbranched-polymer-theranostic
#6
Amanda K Pearce, Joshua D Simpson, Nicholas L Fletcher, Zachary H Houston, Adrian V Fuchs, Pamela J Russell, Andrew K Whittaker, Kristofer J Thurecht
The therapeutic potential of hyperbranched polymers targeted to prostate cancer and loaded with doxorubicin was investigated. Polyethylene glycol hyperbranched polymers were synthesised via RAFT polymerisation to feature glutamate urea targeting ligands for PSMA on the periphery. The chemotherapeutic, doxorubicin, was attached to the hyperbranched polymers through hydrazone formation, which allowed controlled release of the drug from the polymers in vitro endosomal conditions, with 90% release of the drug over 36 h...
July 5, 2017: Biomaterials
https://www.readbyqxmd.com/read/28711565/new-aspects-of-molecular-imaging-in-prostate-cancer
#7
Francesco Ceci, Paolo Castellucci, Juliano J Cerci, Stefano Fanti
Nowadays several new imaging modalities are available for investigating prostate cancer (PCa) such as magnet resonance imaging (MRI) in the form of whole body MRI and pelvic multiparametric MRI and positron emission tomography (PET) using choline as radiotracers. Nevertheless, these modalities proved sub-optimal accuracy for detecting PCa metastases, particularly in the recurrence setting. A new molecular probe targeting the prostate specific membrane antigen (PSMA) has been recently developed for PET imaging...
July 12, 2017: Methods: a Companion to Methods in Enzymology
https://www.readbyqxmd.com/read/28709149/uptake-of-psma-ligands-in-normal-tissues-is-dependent-on-tumor-load-in-patients-with-prostate-cancer
#8
Florian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A Bundschuh, Holger Strunk, Markus Essler
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0...
July 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28707152/-177-lu-psma-radioligand-therapy-for-advanced-prostate-cancer
#9
T Derlin
No abstract text is available yet for this article.
July 13, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28707038/-68-ga-psma-hbed-cc-uptake-in-osteolytic-osteoblastic-and-bone-marrow-metastases-of-prostate-cancer-patients
#10
Jan-Carlo Janssen, Nadine Woythal, Sebastian Meißner, Vikas Prasad, Winfried Brenner, Gerd Diederichs, Bernd Hamm, Marcus R Makowski
PURPOSE: The aim of this study was to evaluate potential differences in "Glu-NH-CO-NH-Lys" radio-labeled with [(68)Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([(68)Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients. PROCEDURES: This retrospective study was approved by the local ethics committee. Patients who received [(68)Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([(68)Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study...
July 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28704341/uptake-of-the-prostate-specific-membrane-antigen-targeted-pet-radiotracer-18f-dcfpyl-in-elastofibroma-dorsi
#11
Michael A Gorin, Wael Mareshdeh, Ashley E Ross, Mohammad E Allaf, Kenneth J Pienta, Martin G Pomper, Steven P Rowe
OBJECTIVE: PET imaging using radiotracers that target prostate-specific membrane antigen (PSMA) are increasingly being used in the evaluation of men with prostate cancer (PCa). It is therefore of increasing importance for imaging specialists to recognize potential pitfalls of this novel imaging technique. In this report, we describe a series of benign elastofibroma dorsi with uptake of the PSMA-targeted PET radiotracer F-DCFPyL. PATIENTS AND METHODS: We retrospectively analyzed the imaging data of 75 men with PCa who were consecutively imaged with F-DCFPyL PET/CT...
July 12, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28701709/psma-expression-by-microvasculature-of-thyroid-tumors-potential-implications-for-psma-theranostics
#12
Andrey Bychkov, Usanee Vutrapongwatana, Supatporn Tepmongkol, Somboon Keelawat
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium, making it a promising target for molecular imaging and therapy. Recently, several studies found unexpected PSMA radiotracer uptake by thyroid tumors, including radioiodine-refractory (RAIR) cancers. PSMA expression was reported in tumor-associated endothelium of various malignancies, however it has not been systematically addressed in thyroid tumors. We found that PSMA was frequently expressed in microvessels of thyroid tumors (120/267), but not in benign thyroid tissue...
July 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28695370/erratum-to-repeatability-of-68-ga-dkfz11-psma-pet-scans-for-detecting-prostate-specific-membrane-antigen-positive-prostate-cancer
#13
Joseph R Osborne, Teja M Kalidindi, Blesida J Punzalan, Kishore Gangangari, Daniel E Spratt, Wolfgang A Weber, Steven M Larson, Naga Vara Kishore Pillarsetty
No abstract text is available yet for this article.
July 10, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28688023/-pet-ct-and-pet-mri-of-the-prostate-from-18-f-fdg-to-68-ga-psma
#14
REVIEW
K Knorr, M Eiber, T Maurer, H-J Wester, K Scheidhauer
CLINICAL/METHODICAL ISSUE: In the last few years nuclear medical diagnostics have experienced a unprecedented renaissance in the diagnostics of prostate cancer, due to the availability of hybrid imaging with positron emission tomography computed tomography (PET/CT), PET magnetic resonance imaging (PET/MRI) and single photon emission computed tomography (SPECT) CT as well as the development of prostate-specific radiopharmaceuticals. METHODICAL INNOVATIONS: The use of fluorodeoxyglucose (FDG), which has been successfully implemented for many years in PET diagnostics, is only helpful in dedifferentiated tumors due to the biological characteristics of prostate cancer...
July 7, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28687599/psma-ligands-for-pet-imaging-of-prostate-cancer
#15
Sarah M Schwarzenböck, Isabel Rauscher, Christina Bluemel, Wolfgang P Fendler, Steven P Rowe, Martin G Pomper, Ali Afshar-Oromieh, Ken Herrmann, Matthias Eiber
Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labelled and (18)F-labelled PET-agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer (PC) has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world due to the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared to standard of care imaging. For high-risk primary PC, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases...
July 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28685078/-68-ga-psma-pet-ct-for-the-detection-of-bone-metastasis-in-recurrent-prostate-cancer-and-a-psa-level-2-ng-ml-two-case-reports-and-a-literature-review
#16
Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho
Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28682848/false-positive-uptake-in-bilateral-gynecomastia-on-68ga-psma-pet-ct-scan
#17
Arun Sasikumar, Ajith Joy, Bindu P Nair, M R A Pillai, Jayaprakash Madhavan
A 66-year-old man on hormonal therapy with prostate cancer was referred for Ga-PSMA PET/CT scan for biochemical recurrence. Ga-PSMA PET/CT scan detected moderate heterogeneous tracer concentration in bilateral breast parenchyma, in addition to the abnormal tracer concentration in enlarged prostate gland, right external iliac lymph node, and sclerotic lesion in L4 vertebra. On clinical examination, he was found to have bilateral gynecomastia. Abnormal concentration of Ga-PSMA in breast cancer is now well known, and in this context, it is important to know that tracer localization can occur in gynecomastia as well, as evidenced in this case...
July 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28677048/a-new-perspective-for-nuclear-medicine-expanding-the-indications-for-psma-targeted-imaging-and-therapy
#18
EDITORIAL
Frederik A Verburg, Markus Luster
No abstract text is available yet for this article.
July 4, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28670175/a-comparative-study-of-68-gallium-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-and-magnetic-resonance-imaging-for-lymph-node-staging-in-high-risk-prostate-cancer-patients-an-initial-experience
#19
Manoj Gupta, Partha S Choudhury, Dibyamohan Hazarika, Sudhir Rawal
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of (68)Gallium ((68)Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent (68)Ga-PSMA PET-CT for staging (December 2014-December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28666778/psma-ligands-in-prostate-cancer-probe-optimization-and-theranostic-applications
#20
REVIEW
Susanne Lütje, Roger Slavik, Wolfgang Fendler, Ken Herrmann, Matthias Eiber
Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as (68)Ga or (18)F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with (131)I or (177)Lu have become available to the clinics, allowing PSMA-based radioligand therapies...
June 28, 2017: Methods: a Companion to Methods in Enzymology
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"